Therapy-related myeloid neoplasms (t-MN), which comprise therapy-related acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and myelodysplastic/ myeloproliferative neoplasms (MDS/MPN), are a late complication of cytotoxic therapy -chemotherapy and/or radiation therapy -used in the treatment of both malignant and non-malignant diseases 1 . There are several clinical subsets of t-MN that correlate with the nature of the prior therapy. The most common subtype (in ~70% of patients) is characterized by loss of part of chromosome 5 (del(5q)) and/or either part or all of chromosome 7 (del(7q) or -7, respectively) and is characteristic of patients who received alkylating agents and/or radiation therapy. Clinically, this subtype has a long latency period (on average five years), presents as MDS, which often progresses rapidly to AML with multi lineage dysplasia, and is associated with a poor prognosis (median survival: 8 months). A second major subset of t-MN is seen in patients who received topoisomerase II inhibitors. Clinically, this subtype has a shorter latency period (in the range of 1 to 2 years), presents as overt leukaemia without an antecedent MDS and is associated with a more favourable response to intensive induction therapy. Translocations involving histone-lysine N-methyltransferase 2A (KMT2A; also known as MLL) at 11q23.3 or runt-related transcription factor 1 (RUNX1; also known as AML1) at 21q22.1 are common in this subgroup.
. There are several clinical subsets of t-MN that correlate with the nature of the prior therapy. The most common subtype (in ~70% of patients) is characterized by loss of part of chromosome 5 (del(5q)) and/or either part or all of chromosome 7 (del(7q) or -7, respectively) and is characteristic of patients who received alkylating agents and/or radiation therapy. Clinically, this subtype has a long latency period (on average five years), presents as MDS, which often progresses rapidly to AML with multi lineage dysplasia, and is associated with a poor prognosis (median survival: 8 months). A second major subset of t-MN is seen in patients who received topoisomerase II inhibitors. Clinically, this subtype has a shorter latency period (in the range of 1 to 2 years), presents as overt leukaemia without an antecedent MDS and is associated with a more favourable response to intensive induction therapy. Translocations involving histone-lysine N-methyltransferase 2A (KMT2A; also known as MLL) at 11q23.3 or runt-related transcription factor 1 (RUNX1; also known as AML1) at 21q22.1 are common in this subgroup.
Historically, t-MN has been considered a consequence of DNA damage induced by cytotoxic therapy in normal haematopoietic stem or progenitor cells. There is currently active debate in the field of cancer biology regarding the relative contributions of inherited risk factors, environmental exposures and stochastic events in the aetiology of cancer. One study estimated that extrinsic factors contribute to 70-90% of the risk in most cancer types 2 . By definition, therapyrelated cancers, also known as second neoplasms, have a strong extrinsic driver (that is, previous chemotherapy and/or radiotherapy). Nonetheless, up to 10% of patients have had more than one previous cancer before their diagnosis of t-MN; thus, the concept that exposure to therapeutic agents is the sole cause of t-MN has been unsatisfactory and raises multiple questions. Such questions include why some people develop t-MN and others do not, why second cancers have a latency of ten years or more in some patients and why t-MN are inherently chemoresistant.
Technological advances such as next-generation sequencing (NGS) have transformed the cancer field. We have learned that 8.5-12.6% of cancer patients have an inherited mutation in a cancer-associated gene compared with 1-2.7% of individuals without cancer [3] [4] [5] . As discussed below, this frequency is likely to be much higher in t-MN patients. Studies are also coalescing that implicate a role for haematopoietic stem cells (HSCs) with acquired somatic mutations existing before treatment of the primary disease and that these HSCs are precursors for t-MN. This knowledge of inherited and pretreatment somatic genetic alterations sheds light on t-MN aetiology and could potentially help identify the long-awaited predictors of who is at risk of developing t-MN.
In this Review, we synthesize recent findings that are reframing our understanding of t-MN patho genesis. We highlight new experimental data that challenge prevailing beliefs regarding t-MN aetiology and show that chemotherapy and/or radiotherapy promotes clonal selection of pre-existing mutant HSCs, in addition to inducing leukaemogenic mutations directly 6 ; t-MNs are genetically and aetiologically similar to other high-risk myeloid neoplasms [6] [7] [8] Acute myeloid leukaemia (AML) . A cancer of the myeloid lineage of haematopoietic cells associated with an expansion of immature cells (≥20% blasts) and defective differentiation into the mature myeloid lineages.
Myelodysplastic syndrome (MDS) . A group of clonal disorders with dysfunctional and dysplastic haematopoiesis of one or more myeloid lineage(s) leading to decreased maturation of normal myeloid cells with <20% blasts and a risk of leukaemic transformation.
Contiguous gene syndrome (CGS) . Genetic disorder caused by chromosomal copy number change, leading to combined dosage imbalance of multiple neighbouring genes typically on the scale of <5 Mb.
but rather are part of a contiguous gene syndrome (CGS) invoking haploinsufficiency [9] [10] [11] and an aberrant bone marrow microenvironment contributes to malignant haematopoiesis [12] [13] [14] [15] . The models described here are not mutually exclusive, and one or multiple different pathways may contribute to these malignancies in any individual patient. Moreover, these paradigms may also apply to other cancers that arise from the interaction between genetics and environment.
Epidemiology
In 2012, there were an estimated 13.7 million cancer survivors in the United States 16 . An ageing population, a commensurate increase in the number of individuals afflicted with cancer, and improvements in oncology care are anticipated to lead to 18 million cancer survivors within a decade 16, 17 . Although progress in treating cancer is welcome, it also creates a need to attend to the long-term health risks of survivors. The incidence of t-MN -currently 0.62 per 100,000 men and women (which accounts for ~10-20% of newly diagnosed cases of AML or MDS 18, 19 ) -is expected to rise in parallel with the increase in the number of cancer survivors worldwide. The median age of individuals diagnosed with t-MN is 64 years, but the disease can occur at any age 20 . Chemotherapy treatment increases the incidence of t-MN by 4.7-fold 21 , and a younger age at the time of exposure further increases that risk 21, 22 . For example, the standardized incidence ratio (SIR) for t-MN is higher for patients treated with chemotherapy for breast cancer at 20-40 years of age compared with those over 60 years of age 21 . The relationship between age at exposure to radiation and risk of t-MN is less clear 23 . Treatment for most primary tumour types carries a risk of t-MN (FIG. 1) . t-MN is rare, although it can occur with high frequency in certain types of cancer. The most common primary malignancies with an associated risk are breast cancer and haematological malignancies (particularly non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma) 21, 23, 24 . Patients with breast cancer in the United States have a 0.5% cumulative 10-year incidence of t-MN 25 , and patients with Hodgkin lymphoma have a cumulative 6-year incidence of 0.9% 26 . Depending on the treatment regimen, up to 10% of patients with non-Hodgkin lymphoma 27 , 8.2% of patients with chronic lymphocytic leukaemia (CLL) 28 and 3.4% of patients with multiple myeloma 29 develop t-MN. Patients with a prior bone or soft-tissue sarcoma are also at particularly high risk for t-MN (FIG. 1) ; up to 11% of patients treated with high-intensity chemotherapy develop t-MN 30 . This relatively higher risk likely stems, in part, from an inherited predisposition to cancer in one-half of these patients 31 .
Changes in treatment protocols, including the decreased use of alkylating agents, have ushered in changes in t-MN incidence. Since 1975, the risk of t-MN in the United States has decreased for patients with ovarian cancer and multiple myeloma 21 (FIG. 1) . By contrast, t-MN risk has increased for patients with non-Hodgkin lymphoma, particularly those who undergo allogeneic HSC transplantation (HSCT) 21 . In the 1990s, a new at-risk population emerged for patients with endometrial cancer, and since 2000, these at-risk populations have expanded to include patients with oesophageal, cervical and prostate cancer 21 . Another growing at-risk population is solid organ transplant recipients, who have an SIR of 4.6 for MDS and 2.7 for AML 22 . The expectation is that progress in developing targeted therapies with reduced nonspecific cytotoxicity will result in a decrease in t-MN incidence.
With respect to the latency period, patients diagnosed with a solid tumour have an increased risk of t-MN within 9 to 12 months after treatment. This risk peaks at 2 years and returns to a population baseline risk in 10-15 years 23 . The development of a t-MN after a primary haematological malignancy follows a broader Nature Reviews | Cancer 
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. The number of cases and standardized incidence ratio (SIR) for t-MN are shown by primary tumour type. The risk of t-MN has decreased over time for patients with multiple myeloma or ovarian cancer (black arrows), whereas the risk has increased for patients with non-Hodgkin lymphoma (grey arrow). CNS, central nervous system.
Standardized incidence ratio
(SIR). The ratio of the observed-to-expected number of cases based on demographic-specific incidence rates of acute myeloid leukaemia (AML) among the general population.
Fanconi anaemia
A bone marrow failure syndrome associated with an inherited mutation in one of at least 17 specific genes associated with the DNA damage response or DNA repair.
De novo AML
Acute myeloid leukaemia (AML) arising without a prior history of exposure to cytotoxic therapies or pre-existing myeloid neoplasm.
time course that peaks at 5 years and does not return to baseline even after 15 years; this risk pattern could be related to an underlying inherited predisposition to haematological malignancies, as discussed below.
Inherited risk factors
By convention, any myeloid neoplasia occurring after cytotoxic exposure is defined as therapy-related. The observation that some t-MN occur decades after cytotoxic therapy raises the question of whether they are a consequence of prior treatment. Instead, some may either represent second cancers arising in patients with a genetic predisposition or result from a stochastic (that is, random) second cancer. Some studies have associated t-MN with common inherited polymorphisms in genes encoding proteins involved in drug metabolism and DNA damage response pathways -for example, NAD(P)H quinone dehydrogenase 1 (NQO1), glutathione S-transferase P1 (GSTP1) and RAD51 (reviewed in REF. 32 ). However, these are low-risk alleles. In the search for higher-penetrance inherited variants, researchers studied cancer survivors who developed t-MN and found that 16-21% of these survivors have a germline mutation associated with inherited cancer susceptibility genes [33] [34] [35] . Churpek and colleagues examined the frequency of germline mutations in 42 breast and ovarian cancer susceptibility genes in 47 breast cancer survivors who developed either a t-MN or therapyrelated acute lymphoblastic leukaemia (ALL) 33 . Ten (21%) had germline mutations in either BRCA1 or BRCA2 (n = 5), TP53 (n = 3), partner and localizer of BRCA2 (PALB2) (n = 1) or checkpoint kinase 2 (CHEK2) (n = 1). Other studies have corroborated germline mutations in BRCA1, BRCA2, TP53 and Fanconi anaemia genes in patients with t-MN [34] [35] [36] [37] [38] [39] . Many of the known t-MN predisposition genes encode components of the DNA damage response, which suggests a model whereby individuals with these germline mutations are particularly susceptible to cytotoxic chemotherapy and/or radiation because they have deficiencies in DNA repair, genomic instability, and/or insufficient cell cycle arrest and apoptosis. Supporting this hypothesis, BRCA1-deficient mice (Brca1 −/− ) exhibit cytopenias, genomic instability and bone marrow failure, and a subset of these mice develop myeloid neoplasms 40 . Interestingly, breast cancers arising in patients with germline BRCA1 or BRCA2 mutations are associated with concurrent somatic TP53 mutations, suggesting cooperativity of these genes 41, 42 . We postulate that TP53 dysfunction is integral to BRCA1 or BRCA2 mutation-associated tumours and potentially selects for the high frequency of TP53 mutations in t-MN, a disease that is also characterized by defects in the DNA damage response 43 . An alternative but not mutually exclusive model is that genetically susceptible patients are at risk for the independent development of a second malignancy. Support for this model includes the extended latency period to t-MN development in patients with BRCA1 or BRCA2 mutations of 133 months 33 . In addition, among ten patients with germline mutations in any cancer susceptibility gene, five had either normal karyotypes or balanced recurring translocations in their leukaemia cells, which are cytogenetic findings more typical of de novo AML 24, 33 . This supports the hypothesis that myeloid neoplasms arising in some genetically susceptible hosts are minimally influenced by the prior treatment and may represent independent second primary cancers.
Furthermore, germline mutations in genes other than those involved in the DNA damage pathways may interact with genotoxic cancer therapies to induce t-MN. For example, children with germline mutations of neurofibromin 1 (NF1), which encodes a negative regulator of RAS signalling, are at an elevated risk of developing t-MN 44 . Consistent with this idea, heterozygous Nf1 mutant mice are strongly predisposed to radiation-induced myeloid neoplasms 45, 46 . It is likely that expanding these studies to include larger gene panels or whole-genome sequencing in conjunction with the analysis of a larger cohort of patients will increase the number of known susceptibility genes and the frequencies of inherited risk alleles. Overall, emerging data emphasize the need to account for germline variants in the diagnosis and management of t-MN.
Exposures
Chemotherapy. The risk of developing t-MN is likely to be determined by a complex interaction between the nature and dosage of the chemotherapeutic agent, the radiation intensity, genetic factors, the environment, comorbidities and the age of the patient. Although any cytotoxic agent can increase the risk of t-MN, alkylating agents and topoisomerase II inhibitors in particular are known to be causative (TABLE 1) . Alkylating agents covalently modify the DNA, causing DNA crosslinking, DNA double-stranded breaks (DSBs), mutations and cytotoxicity. The cumulative dosage correlates with the incidence of t-MN, and some alkylating agents are more leukaemogenic than others 47, 48 . Alkylating agents are 
Brachytherapy
The use of radioactive sources implanted into the tumour tissue.
Knudson's two-hit hypothesis
A model stating that tumour suppressor genes are recessive and that inactivation of both alleles is required for a malignant phenotype.
5q-syndrome
A subset of MDS with an interstitial deletion of 5q as the sole cytogenetic abnormality (or with one additional abnormality). These patients present with macrocytic anaemia, megakaryocytic dysplasia and preserved or elevated platelet counts; additionally, they have a relatively favourable prognosis.
associated with longer latency to t-MN, a presentation of MDS that often progresses to AML, deletions of chromosome 5, loss or deletion of chromosome 7 and a poor prognosis 24 . Platinum-based chemotherapeutic agents have a weaker association with t-MN 49, 50 . Topoisomerase II inhibitors induce DNA DSBs by preventing the religation of the DNA strands cleaved by topoisomerase II, which facilitates unwinding of the DNA during replication, and are correspondingly linked with balanced translocations 24 . Since myeloid leukaemias with balanced translocations, such as translocations involving KMT2A at 11q23.3, RUNX1 at 21q22.1 or the promyelocytic leukaemia-retinoic acid receptor α (PML-RARA) fusion resulting from the t(15;17), have the fewest cooperating mutations 51 , it is possible that the acquisition of multiple cooperating mutations is not required for leukaemogenesis and can explain why topoisomerase II inhibitor-associated t-MN has a shorter latency and presents as overt AML 24 . t-MN is also associated with prior exposure to the antimetabolites azathioprine and fludarabine 52, 53 . However, it is difficult to parse out a definitive leukaemogenic role for other classes of drugs such as tubulin inhibitors, hydroxyurea, growth factors or other antimetabolites. This is partly because most patients receive combination therapies but may also be due to the weaker contributions of these other classes of drugs to t-MN. Among patients with ovarian cancer with germline BRCA1 or BRCA2 mutations, 0.8-2% developed t-MN after therapy with olaparib, a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor, which suggests a unique susceptibility worthy of further study 54 .
Radiation. Studies of atomic bomb survivors established radiation as a potent leukaemogen 55 . In cancer therapy, the incidence of myeloid neoplasia is proportional to the prior radiation dose 56 , whereas the addition of radiation to a chemotherapy regimen increases the risk of t-MN in some, but not all, disease contexts 56 . For example, the risk of t-MN increases with combined modality treatment for lung and breast cancer, but this effect was not observed in patients with non-Hodgkin lymphoma, Hodgkin lymphoma or multiple myeloma 23 . The influence of radiation exposure was less apparent for these haematological malignancies, perhaps owing to the potency of the chemotherapy and/or the radiation field. It also remains possible that patients with primary haematological malignancies possess an underlying genetic predisposition that masks an additive effect of radiation.
The role of radiation therapy as a sole risk factor for t-MN development has been controversial. In t-MN that manifest following radiation monotherapy, 60% have abnormalities of chromosomes 5 and/or 7, which are similar to the cytogenetic abnormalities associated with alkylating agents; furthermore, t-MN due to radiation therapy present with a similar clinical and morphological profile to those associated with alkylating agent therapy 24 . The hope is that decreasing radiation fields of exposure and doses will be less leukaemogenic, as suggested by a more recent cohort of t-MN patients receiving radiation monotherapy who had clinical and cytogenetic features more similar to de novo myeloid neoplasms 57 . Furthermore, external beam radiotherapy or brachytherapy for prostate cancer may not be associated with an increased risk of MDS 58 .
Somatic CGSs
The spectrum of genomic abnormalities in t-MN parallels that of de novo myeloid neoplasms, with the key distinction that t-MN is markedly skewed towards high-risk abnormalities 8 . Del(5q), -7/del(7q), complex karyotypes and TP53 mutations all carry an adverse prognosis, and they are all profoundly over-represented in t-MN compared with de novo counterparts of t-MN 24 (FIG. 2) . In contrast, favourable-risk abnormalities such as the t(8;21) or intermediate-risk normal karyotypes are considerably under-represented 24 . In this regard, t-MN parallels other high-risk myeloid neoplasms, namely, secondary AML arising from MDS 59 and de novo AML in elderly people 60 .
A striking 70% of t-MN possess del(5q) or -7/del(7q) abnormalities as a result of deletions of the long arm of chromosome 5 or the loss or deletion of chromosome 7, respectively 24 . Long-standing efforts to identify a putative single tumour suppressor gene encoded within each of the commonly deleted regions were influenced initially by the dogma of Knudson's two-hit hypothesis and have been complicated more recently by the recognition of many potentially cooperating candidate genes within the deleted segments, suggesting the existence of CGSs within these loci (FIG. 3) . With the exception of the gene that encodes polycomb repressive complex (PRC) component enhancer of zeste homologue 2 (EZH2) 61 , 5q and 7q tumour suppressor genes have haploinsufficient phenotypes, and there is rarely a second inactivating mutation of the remaining allele 62 . Without a canonical 'second hit' to identify the tumour suppressor gene or genes, investigators mapped minimally deleted regions (MDRs) by examining large numbers of patients with myeloid neoplasms [62] [63] [64] [65] .
A CGS on the long arm of chromosome 5 (5q). There are two MDRs on chromosome 5q: 5q31.2 in patients with t-MN, de novo AML and high-risk MDS 63 ; and 5q32 in those with 5q-syndrome, also known as MDS with isolated del(5q)
. Although earlier studies focused on genes in the MDRs, it is becoming clear that genes outside the MDR also contribute to disease. Moreover, the deletion in virtually all patients is large (~70 Mb), spanning 5q14-q33 and encompassing both MDRs, which makes it challenging to identify the involved genes 63, 66 . Haploinsufficient genes implicated in del(5q) drive distinct disease characteristics, namely, anaemia (ribosomal protein S14 (RPS14) and adenomatous polyposis coli (APC)), megakaryocytic dysplasia (microRNA genes mir-145 and mir-146A), HSC expansion (early growth response 1 (EGR1), APC, and casein kinase 1 α 1 (CSNK1A1)) and clonal dominance (CSNK1A1) [67] [68] [69] [70] [71] [72] . Including APC, 5q14-q33 contains a total of 17 genes encoding components and regulators of WNT signalling, a pathway integral to haematopoiesis and leukaemogenesis 73 .
A CGS describes a disease involving multiple dose-sensitive genes within a genomic interval 74 in which an en bloc segmental deletion is more pathogenic than inactivation of any single gene. For example, Trp53 reduction combined with haploinsufficiency of the 5q-encoded gene Egr1 does not lead to overt leukaemia in mice, whereas Trp53 reduction in combination with haploinsufficiency of the 5q-encoded genes Apc and Egr1 does 9 . CGSs in cancer can occur with other recurring deletions in myeloid neoplasms, that is, del(7q) (see below), del(20q) and deletions encompassing TP53 at 17p13.1 (REF. 75 ), RB1 at 13q 76 and MYC at 8q24.21 (REF. 77 ), to name a few. Additionally, these CGSs may be relevant to the large segmental deletions characteristic of common epithelial tumours, such as breast, colon and lung carcinomas 78 .
A CGS on 7q. Chromosome arm 7q contains three MDRs (FIG. 3) . At 7q22, cut like homeobox 1 (CUX1) is a haploinsufficient tumour suppressor gene that is recurrently mutated in haematopoietic malignancies and solid tumours 10, 79 . The genetic evidence for CUX1 acting as a tumour suppressor gene is strong, as heterozygous CUX1-inactivating mutations are independently associated with a poor prognosis 79 . Heterozygous deletion of a 2 Mb syntenic interval near Cux1 led to features of MDS in mice, demonstrating that 7q22 is also a CGS region 11 . The 7q34 locus contains LUC7 like 2, pre-mRNA splicing factor (LUC7L2), which encodes a spliceosomal Nature Reviews | Cancer ETV6, ETS variant 6; EZH2, enhancer of zeste homologue 2; FLT3, fms related tyrosine kinase 3; IDH1, isocitrate dehydrogenase 1; ITD, internal tandem duplication; JAK2, Janus kinase 2; KMT2A, histone-lysine N-methyltransferase 2A; NF1, neurofibromin 1; NPM1, nucleophosmin 1; PHF6, PHD finger protein 6; PTPN11, protein tyrosine phosphatase, non-receptor type 11; RUNX1, runt related transcription factor 1; SETBP1, SET binding protein 1; SF3B1, splicing factor 3b subunit 1; SMC, structural maintenance of chromosomes; SRSF2, serine and arginine rich splicing factor 2; STAG2, stromal antigen 2; TET2, tet methylcytosine dioxygenase 2; U2AF1, U2 small nuclear RNA auxiliary factor 1; WT1, Wilms tumour 1; ZRSR2, zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2. *Denotes that del(5q), -7/del(7q) and a complex karyotype can co-occur in the same patient; thus, these frequencies partially overlap. ‡ Of note, 17p deletions are often cryptic and therefore are under-reported by conventional cytogenetic analysis. Thus, the numbers shown may represent the lower range of the true frequency.
Ataxia-pancytopenia syndrome
Also known as myelocerebellar disorder; associated with ataxia, bone marrow failure and a predisposition to myeloid leukaemia with monosomy 7.
Revertant mosaicism
When a disease-causing mutation is spontaneously somatically corrected for and the corrected cell clonally expands.
Shwachman-Diamond syndrome
An inherited disorder associated with skeletal abnormalities, exocrine pancreatic insufficiency and bone marrow failure that may progress to myeloid leukaemia with chromosome 7 abnormalities.
protein that is mutated in myeloid malignancies 80 . A third MDR at 7q35-q36 contains cullin 1 (CUL1) and EZH2, both of which have been reported to be somatically mutated in myeloid neoplasms 61, 80 . This distal CGS segment also contains the haploinsufficient tumour suppressor gene KMT2C (also known as MLL3) 81 . Monosomy 7 or large 7q deletions will include sterile alpha motif domain containing protein 9 like (SAMD9L) at 7q21.2; this gene encodes a facilitator of endosome fusion 82 . Inherited SAMD9L mutations cause ataxia-pancytopenia syndrome and a predisposition for AML with monosomy 7 (REF. 83 ). These patients have been observed to develop mosaic 7q loss of heterozygosity in their peripheral blood cells, leading to loss of the mutant SAMD9L allele 83 . This is intriguing because revertant mosaicism of chromosome 7 has been reported in Shwachman-Diamond syndrome 84 , a syndrome linked to SBDS gene mutations at 7q11.21 and a predisposition to AML with -7/del(7q). SAMD9 encodes a SAMD9L paralogue and is located on chromosome band 7q21.2. Adaptation by aneuploidy is also reported in patients with SAMD9 mutations with a predisposition to MDS with monosomy 7 (REF. 85 ). The mutated SAMD9 and SAMD9L proteins in these patients were found to restrict cell growth more than their wild-type counterparts. Thus, cells from individuals exhibiting a loss of heterozygosity of chromosome 7, which carries the mutant allele may have undergone adaptation to the growth restriction. It is tempting to speculate that monosomy 7 in some diseases with a predisposition to AML with -7/del(7q) is a consequence of the pressure for revertant mosaicism.
Somatic gene alterations NGS of genomes has yielded surprising results and transformed our understanding of the aetiology and pathogenesis of t-MN. The most comprehensive (REFS 64, 184, 185) are shown. In myeloid neoplasms, there is evidence for a role for haploinsufficiency of the following genes on 5q: adenomatous polyposis coli (APC) 67 , TRAF-interacting protein with forkhead-associated domain B (TIFAB) 186 and early growth response 1 (EGR1) 187 . Heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) 188 , heat shock protein family A (Hsp70) member 9 (HSPA9) 189 , diaphanous related formin 1 (DIAPH1) 190 , and sprouty 4 (SPRY4) 191 have been implicated based on mouse models, and mutations of cell division cycle 25C (CDC25C) 192 have been identified in familial platelet disorder (FPD) progressing to acute myeloid leukaemia (AML). CTNNA1 (encoding α-catenin) 193 has been implicated in some, but not all, studies. The microRNA genes mir-145 (REF. 69 ) and mir-146A
69
, casein kinase 1 α 1 (CSNK1A1) 71 , secreted protein acidic and cysteine-rich (SPARC) 194 , and ribosomal protein S14 (RPS14) 68 have been implicated in the pathogenesis of myelodysplastic syndrome (MDS) with an isolated del(5q). On 7q, there is evidence for a role in myeloid neoplasia for these genes: sterile alpha motif domain containing protein 9 (SAMD9) 85 , SAMD9L 82, 83 , cut like homeobox 1 (CUX1) 10 , histone-lysine N-methyltransferase 2E (KMT2E) [195] [196] [197] , dedicator of cytokinesis 4 (DOCK4)
198
, LUC7 like 2, pre-mRNA splicing factor (LUC7L2) 80 , cullin 1 (CUL1) 80 , enhancer of zeste homologue 2 (EZH2) 199 and KMT2C (also known as MLL3) 81 . Blue boxes indicate genes significantly and recurrently mutated in pan-cancer analysis 200 . Yellow boxes indicate genes recurrently mutated in myeloid neoplasms. Pink boxes indicate genes recurrently mutated in both myeloid and pan-cancer. Note that KMT2C mutations may be overestimated due to a pseudogene causing false-positive mutations 201 . t-MN, therapy-related myeloid neoplasms. *Genes with inherited mutations that are associated with a predisposition to myeloid dysplasia are indicated. 
Aplastic anaemia
study published to date analysed the whole genomes of 22 patients with t-MN as well as 149 AML and/or MDS-related genes in an additional 89 patients 6 . The expectation was that because all 22 patients had been exposed to chemotherapy and/or radiation therapy for their primary diseases, the burden of somatic mutations would be greater than that found in de novo AML due to the ensuing DNA damage 6 . Surprisingly, the numbers of single nucleotide variants (SNVs) and small insertions and deletions (indels) as well as copy number alterations (CNAs) were similar in t-MN and de novo AML, with each t-MN genome carrying ten SNVs or indels in coding regions 6 . Overall, this is one of the lowest mutational burdens across human cancers 86 . We also noted a low mutational load in the exome and RNA-sequencing analysis of ten t-MN cases 87 . Similarly, a study of the mutations in 53 genes in 70 t-MN patients found that the mutation rate was comparable to that of de novo AML and/or MDS 7 . These findings are contrary to the historical premise that t-MN largely arises owing to chemotherapy and/or radiation-induced mutations.
Furthermore, if chemotherapy drives somatic mutational changes in t-MN, it would be expected to leave a signature in the mutation spectra. Alkylating agents preferentially induce transition-type mutations 88 , and this signature is apparent in glioblastomas in patients who were pretreated with alkylating agents before surgical resection 86 . Even though at least half of the t-MN patients had a history of exposure to an alkylating agent, the frequency of transition-type mutations was similar in t-MN patients compared with de novo AML 6 . Thus, the lack of a chemotherapy-induced mutational signature combined with the surprisingly low mutational load suggests that treatment-induced mutation is not the only or major driver of t-MN. In addition, the low number of DNA base-level mutations raises the question of whether largescale genomic alterations such as chromosomal deletions or balanced translocations are the critical defects in the pathobiology of t-MN. Nonetheless, it cannot be ruled out from these studies that chemotherapy induces mutations in some cases. For example, there is a clear relationship between the mechanism of action of topoisomerase II inhibitors and the induction of balanced translocations 24, 89 (FIG. 4) . In contrast, alkylating agents can cause DNA DSBs, which can lead to a chromosomal deletion 90 . On average, seven somatic CNAs have been identified in t-MN patients who received prior alkylating agent therapy (James Downing and Joy Nakitandwe, unpublished data), whereas CNAs are infrequent in patients treated with a topoisomerase II inhibitor 6 . CNAs are skewed 2:1 in favour of loss versus gain of chromosomal material, with patients possessing a del(5q) abnormality showing a 2-fold increase over the average; this frequency is consistent with the association with a complex karyotype.
In addition to a comparable number of mutations and type of mutation, a growing number of studies report that the mutated genes and altered pathways -that is, genes encoding components of the spliceosome, chromatin modifiers, transcription factors and receptor tyrosine kinase signalling proteins -are completely overlapping in t-MN and de novo AML (FIG. 2) . Ebert and colleagues 8 report that the overall spectrum of mutated genes in t-MN is indistinct from that in de novo AML. t-MN somatic mutations were more akin to de novo AML with the same cytogenetic changes than to t-MNs with other cytogenetic changes. Thus, the emerging pattern indicates that when analyses control for karyotype, de novo AML and t-MN are indistinguishable at the genetic level. In other words, t-MN have a significantly higher frequency of high-risk karyotypes (for example, complex karyotypes and abnormalities of chromosomes 5 and/or 7 are seen in ~70% versus 20% in cases of de novo AML), but t-MNs with high-risk karyotypes are indistinguishable from the mutational, clinical and morphological profile of de novo AML with comparable high-risk karyotypes.
In t-MN, there are two broad genetic pathways that account for the majority of cases. TP53 mutations define the first and occur in up to 37% of t-MN 91 . t-MN and de novo AML with TP53 mutations are associated with del(5q) abnormalities in ~80% of cases as well as complex karyotypes, resistance to therapy and poor overall survival 92 . The -7/del(7q) abnormality defines the second major subgroup of t-MN, occurs in 49% of patients 24 and is associated with mutations that activate the RAS pathway in both de novo AML and t-MN 87, 93 . Although this subgroup also has a poor prognosis, the development of RAS pathway inhibitors provides some therapeutic promise 94 . There is partial overlap between the TP53-mutated subgroup and the -7/del(7q) subgroup, as the -7/del(7q) abnormality may also occur in TP53-mutated cases, typically in the context of a del(5q) abnormality and a complex karyotype 24, 87 . The remaining t-MN cases that do not fall into these two ontogenies are akin to de novo counterparts (defined by balanced translocations or a normal karyotype with nucleo phosmin 1 (NPM1) and/or fms related tyrosine kinase 3 (FLT3) mutations, among others) 8 . To date, there is no clear sequence of genetic events that produce t-MN, and multiple scenarios likely exist. TP53 mutations can be the initiating lesion in some t-MN 6, 95 . In MDS with a del(5q), this deletion is the initiating defect in up to 73% of cases, and TP53 mutations are acquired as a secondary cooperating mutation associated with a high risk of progression to AML 96, 97 . Monosomy 7 occurs in the absence of recurrent gene mutations in most MDS cases associated with aplastic anaemia 98 . Future studies to illuminate the sequence of events and how the order of mutations alters the disease phenotype will be informative.
The role of clonal haematopoiesis
In 1993, Cachia et al. 99 reported a higher frequency of clonal haematopoiesis in patients who had received cytotoxic therapy for lymphoma and presciently suggested that these patients should be followed prospectively for t-MN development. More recent reports suggest that up to 15% of patients with breast and/or ovarian cancer who were treated with one round of chemotherapy and 27% of patients who received two rounds of chemotherapy developed clonal haematopoiesis [100] [101] [102] . Clonal haematopoiesis of indeterminate potential (CHIP) is the presence of a clonal population of haematopoietic cells with a somatic mutation in a gene associated with haematological malignancies in the absence of morphological evidence of disease. The fundamental role of CHIP in the pathogenesis of t-MN is now becoming apparent 103 . Almost 1% of healthy individuals harbour clonal, somatic, numerical or structural chromosomal changes in the blood [104] [105] [106] [107] . The frequency increases to 2-3% in individuals over age 60 (REFS 106, 107) , and some clones expand over time 105, 108 . The types of abnormalitysuch as del(20q), del(13q), del(11q), trisomy 8 or, less commonly, del(5q) or del(7q) -even include those found in haematological malignancies 104, 105, 107 . Not surprisingly, clonal mosaicism for structural rearrangements carries a tenfold increased risk of a subsequent haematological malignancy 107, 109 . NGS studies of peripheral blood lymphocytes have identified that gene-level somatic mutations and evidence of CHIP increase in incidence with age and have an association with the subsequent development of a haematological cancer [110] [111] [112] [113] . Ultrasensitive sequencing There are four main drivers for therapy-related myeloid neoplasm (t-MN) development. These pathways are not mutually exclusive, and one or multiple pathways may contribute to t-MN development in any individual patient. a | Patients with an inherited mutation in a gene encoding a component of the DNA damage response and DNA repair pathways have an increased susceptibility to the development of multiple, independent malignancies. In addition, these patients may have increased susceptibility to chemotherapy and/or radiation-induced mutations due to an impaired DNA damage response or DNA repair pathway. b | The role for therapy as a mutagen is illustrated. In the prevailing model of t-MN, chemotherapy and/or radiation induces DNA damage that leads to transformation. An example of this is topoisomerase II inhibitor-induced translocations. c | The role for therapy as a driver of clonal selection is shown. In patients with a pre-existing somatic mutation and clonal haematopoiesis, that is, clonal haematopoiesis of indeterminate potential (CHIP), chemotherapy and/or radiation gives these clones a competitive advantage over normal haematopoietic stem cells (HSCs). The consequences of the somatic mutation -for example, genetic instability associated with mutant TP53 -combined with regenerative haematopoiesis facilitates the acquisition of subsequent mutations and t-MN development. d | Chemotherapy and/or radiation also induce damage to the bone marrow stromal niche. Alternatively, the bone marrow microenvironment may be altered or damaged as a result of normal processes, for example, ageing. Altered niche function, such as a pro-inflammatory response, may promote clonal selection and/or produce factors that favour leukaemia-initiating cells. Chr., chromosome; mut, mutant; PML, promyelocytic leukaemia; RARA, retinoic acid receptor α.
revealed CHIP in 19/20 (95%) healthy individuals 50-60 years of age 114 . The genes mutated in CHIP are also recurrently mutated in myeloid malignancies, for example, DNA methyltransferase 3A (DNMT3A), additional sex combs like 1 (ASXL1), tet methylcytosine dioxygenase 2 (TET2) and TP53.
How might pre-existing somatic mutations and CHIP relate to t-MN? Over 20 genes provide an engraftment advantage to HSCs when inactivated 115 , including DNMT3A in humans and Tet2 in mice [116] [117] [118] . We propose a model whereby mutated HSC clones with a 'fitness' advantage will preferentially survive during chemotherapy and/or radiation and then repopulate the haematopoietic compartment. Those same mutations may also cause abnormal differentiation and genomic instability, which is a recipe for dysfunctional haematopoiesis and, ultimately, transformation. The relative risk of individual mutant genes and structural rearrangements for subsequent t-MN is an active area of investigation.
Recent reports have established direct links between pre-existing somatic mutations and t-MN. Wong and colleagues 6 identified somatic TP53 mutations in the blood of healthy individuals. They and others demonstrated that TP53 mutations are detectable in the blood of some patients with t-MN before their exposure to chemotherapy for the primary malignant disease 6, 95 . In addition, HSCs from Trp53 +/− mice have a clonal advantage after chemotherapy and/or radiation 6, 119 . Expanding on this result, a retrospective study of t-MN patients identified CHIP in 10/14 (71%) patients at the time of the primary malignancy before they received treatment 120 . Two additional retrospective studies reported CHIP in 62-66% of t-MN patients at the time of the primary malignancy, although most of these patients had already received some type of treatment 121, 122 . The positive predictive value of CHIP for the development of t-MN was 27-35%, and the negative predictive value was 89-98%, thereby providing the first potential biomarker for t-MN 120, 121 . There is some indication that certain mutated CHIP genes are more predictive of subsequent t-MN. However, the number of patients studied is currently too small to achieve a consensus on which genes are more informative. Higher clonal frequency and more than one gene mutation also indicated a greater risk of t-MN 120, 122 . Whether the presence of multiple mutations occurs within the same clone and whether this is clinically meaningful remains unknown. In most cases, the mutation present in the CHIP clone was identified in the t-MN and likely drove the pathogenesis of the myeloid neoplasm. However, in a few patients, the CHIP mutation was not present in the t-MN, suggesting that, in these cases, CHIP may indicate diseased bone marrow and/or genetic instability. In light of the finding suggesting that most individuals over the age of 50 have CHIP 114 , it is imperative to define the features of CHIP that are clinically relevant and predictive of the development of subsequent myeloid neoplasia.
In summary, there is strong evidence that chemotherapy and/or radiation creates an environment that selects for pre-existing mutant clones at the expense of normal, healthy HSCs (FIG. 5) . This also partially explains why t-MN are inherently resistant to treatment: the mutant leukaemia-initiating clones have already undergone one or more rounds of selection for increased 'fitness' in response to chemotherapy and/or radiation.
It could be argued that clonal selection is the origin of other high-risk myeloid neoplasms with inherent chemoresistance
. AML in elderly people has highrisk clinical and genetic features often indistinguishable from t-MN 60 . In this instance, HSC oligoclonality associated with normal ageing and increased potential for chemical and/or environmental exposures during the lifetime of an individual may drive HSC selection. Clonal competition may arise during regenerative haemato poiesis driven by normal processes, such as ageing, inflammation, immune destruction, viral infections, defects in the bone marrow niche and/or dysfunctional haematopoiesis, as found in aplastic anaemia and MDS. Indeed, CHIP occurs in 47-73% of patients with aplastic anaemia, a patient population with a known risk of developing either AML or MDS with high-risk cytogenetic features [123] [124] [125] . Likewise, secondary AML arising from MDS has high-risk features akin to t-MN 59 .
The role of the bone marrow niche Recent studies highlight the role of the complex bidirectional crosstalk between HSCs and the bone marrow niche in normal haematopoiesis as well as in the pathogenesis of myeloid diseases [12] [13] [14] [15] . Multiple cell types contribute to the niche, including various mesenchymal stromal cell (MSC) populations and progeny cells derived from MSCs, such as osteoblasts 126 . Emerging data suggest that niche alterations play a role in the pathogenesis of myeloid neoplasms [12] [13] [14] [15] , although these results are not fully understood. Functional defects of the MDS and/or AML niche have been noted, such as a decrease in the production of HSC-supportive factors 127, 128 , and may account in part for the poor results of HSC transplantation in patients with t-MN and high-risk MDS and AML. Medyouf et al. 128 showed that MSCs from MDS patients have a perturbed differentiation programme and are essential for the propagation of MDS HSCs (CD34 ) led to the development of MDS and AML 13, 15, 129, 130 . In the past decade, alterations in several cellular pathways in the bone marrow niche have been implicated in the aetiology of myeloid diseases. Canonical WNT signalling plays a role in the regulation of haematopoiesis, the aberrant renewal of leukaemia stem cells and the maintenance of bone marrow niche function 131, 132 . Gene expression profiling of haematopoietic cells has identified WNT pathway activation in MDS, AML and t-MN with del(5q) 73, 133, 134 . Deregulation of WNT-β-catenin signalling in cancer has been correlated with genomic instability, raising the possibility that this pathway contributes to genomic instability and complex karyotypes characteristic of this subtype of t-MN. In parallel, activation of β-catenin, the nuclear mediator of WNT signalling, was observed in osteoblastic cells of the bone marrow niche with a resultant increase in Notch signalling in HSCs in ~40% of MDS and AML patients studied, most (80%) of whom had del(5q) and/or -7/del(7q) abnormalities 135 . In elegant work using mouse models of MDS, Zambetti et al. 136 established mechanistic links between inflammation and cancer. Specifically, they demonstrated that overexpression of the damage-associated molecular pattern (DAMP) genes S100A8 and S100A9 in the mesenchymal niche cells drives genotoxic stress in HSCs via activation of the p53-S100A8/9-Toll-like receptor 4 (TLR4) signalling axis. Moreover, transcriptional activation of this signalling axis in the bone marrow niche predicted progression to AML and survival in patients with MDS, providing a rationale for therapeutic targeting of the bone marrow niche-based inflammatory signalling in some myeloid disorders 136 .
What then is the role of cytotoxic therapy in this process? The answer is likely to be complex, as cytotoxic therapy has been shown to exert a number of effects on the bone marrow microenvironment, including a pro-inflammatory response and the consequent release of inflammatory cytokines, for example, tumour necrosis factor (TNF), transforming growth factor β (TGFβ), and interleukin-6 (IL-6); the release of reactive oxygen species (ROS) by MSCs with resultant genotoxic damage to HSCs; injury to sympathetic nerves and remodel ling of the bone marrow niche. In a mouse model of t-MN, based on haploinsufficiency of two del(5q) genes, Egr1 and Apc, together with Trp53 knockdown, Stoddart et al. 130 observed a high frequency of myeloid diseases following concurrent treatment of both haematopoi etic cells and the bone marrow stroma with an alky lating agent, but not after treatment of either alone. These observations reinforce the role of the intricate bidirectional interplay between mutant haematopoietic stem and progenitor . Over time, mutant clones can acquire additional mutations due to mutations in DNA damage response genes and/or increased proliferation in the context of regenerative haematopoiesis. In haematopoiesis, competition arises in a number of different contexts. Loss of HSC diversity with age and the cumulative lifetime exposure to toxins and drugs, among other factors, may select for mutant clones that ultimately give rise to myeloid neoplasms in elderly people. Chemotherapy and radiation exposure promotes therapy-related myeloid neoplasms (t-MN). Inflammation, immune destruction and dysfunctional haematopoiesis (including bone marrow niche-based effects) can give rise to secondary myeloid neoplasms arising from aplastic anaemia (AA) or myelodysplastic syndrome (MDS). Regardless of the selective pressure, the competitive filter increases the likelihood that the malignant clones will have inherent resistance to therapy. In contrast, a stochastic mutation that gives rise to AML without an antecedent clonal selection is more likely to be a lower-risk disease. 137 proposed that HSC-extrinsic factors such as cytotoxic therapy, toxins, infection and/or inflammation, or auto immunity -processes known to impact the bone marrow niche -may transiently reduce the size of the HSC pool and contribute to clonal selection of mutant HSCs and subsequent disease development. There is strong evidence that cytotoxic therapy creates an environment that selects for pre-existing mutant clones at the expense of normal, healthy HSCs. In this context, DNA damage-induced competition led to a selective clonal advantage of HSCs and haematopoietic progenitor cells with reduced p53 function (and possible clonal expansion of emerging cancer cells) in mouse bone marrow chimaeras -reminiscent of the CHIP phenotype -via growth arrest and senescence-related gene expression in cells with higher p53 activity 119 . Additionally, this competition possibly induced the expression of genes that reduce apoptosis. Interestingly, the extent of cell competition as a result of reduced p53 levels and the corresponding selective advantage was greater in individuals with a smaller proportion of p53-deficient cells in the initial haematopoietic stem or progenitor cell population. This was possibly due to the phenomenon of 'frequency-dependent selection' , whereby rare p53-low cells largely compete with cells with wildtype levels of p53 rather than with each other. Moreover, genes encoding proteins involved in interactions between haematopoi etic cells and cells of the microenvironment (for example, adhesion and migration) were differentially expressed in HSCs with a clonal selective advantage, implicating a role for p53 levels in mediating a gene expression profile in HSCs that can alter interactions with the stroma. This 'clonal selection model' is a paradigm shift and will impact our understanding of the biology of t-MN, the development of treatments to prevent t-MN and the screening methods to use for t-MN.
In summary, studies in mouse models and in patients have indicated that treatment-induced mutations in HSCs are not the only driver of t-MN and additional factors, such as bone marrow niche-induced changes, also influence disease pathobiology. Specifically, bone marrow stromal changes and the formation of a malignant niche are not merely a consequence of the malignant process but contribute directly to the pathogenesis of the disease.
Prognosis
The outcome for t-MN patients is poor, with a 5-year survival of 10% 20 . In the largest study carried out by a single institution, which recruited 303 t-MN patients between 1972 and 2001, the median survival was 8.0 months 24 . Two decades later, a modest improvement in survival (14.6 months) was reported in a multicentre study of 277 patients recruited between 1999 and 2013 (REF. 20) . Older age at t-MN diagnosis, unfavourable karyo type (FIG. 2) , low haemoglobin and low platelet counts portend a worse outcome 20 . Compared with patients with de novo AML, t-MN patients are more likely to have high-risk karyotypes, comorbidities and poor performance status 138 . In a study that adjusted for these confounding factors, it was found that among patients 60 years or older with a high-risk karyotype and who were undergoing intensive therapy, t-MN patients had a similar outcome as patients with de novo AML 138 . This observation suggests that these diseases are biologically similar in older patients. For younger patients and patients with favourable-risk karyo types, t-MN is an independent adverse prognostic indicator [138] [139] [140] . HSCT significantly improves patient survival to 58.8 months and is the only potentially curative treatment. Despite this, it has only been performed in less than 20% of cases 20 . t-MN patients are often excluded as candidates for allogeneic HSCT due to poor performance status, advanced age and the lack of a matched donor. For those patients who receive a transplant, overall survival is 38% at five years and 24% at ten years 141 . Emerging data indicate that not all patients may benefit from transplantation; MDS patients with TP53 mutations have a median overall survival of just 4.6 months after HSCT 142 . This is sobering news, as up to 40% of t-MN patients have TP53 mutations 91 . Conversely, the addition of decitabine to transplant regimens may benefit patients with TP53-mutant AML and MDS 143 . However, the molecular mechanism underlying the sensitivity of TP53-mutated disease to decitabine is currently unclear.
Therapeutic implications
The knowledge gained in studying t-MN aetiology opens preventive and therapeutic opportunities but raises a number of new questions. The burden of rare, inherited, deleterious variants needs to be fully characterized by performing genome-wide analyses in cohorts of t-MN patients with and without a family history of cancer. Prospective trials of cancer patients are necessary to definitively ascertain the genetic risks of subsequent t-MN, with the caveat that the risk of t-MN is strongly influenced by the therapeutic regimen and will therefore change over time. These studies should determine regenerative growth, chemotherapy, radiation, chemical exposure, infections, inflammation, immune destruction, oligoclonal stem cells associated with ageing and defects in the niche 5. Clones acquire additional mutations due to increased cell division and/or inactivation of the DNA damage response pathway 6. The malignant clones have inherent resistance to therapy because they have already undergone one or more rounds of selection for increased 'fitness' in response to competitive pressures the degree to which germline mutations in t-MN susceptibility genes correlate with subsequent t-MN. We also need to perform prospective trials to define the extent to which CHIP can be used as a biomarker for stratifying t-MN risk. Specific questions in this area include determining the genes and individual genetic changes that are present, the clonal frequencies of these changes and the multiple gene mutations (and possibly specific combinations of mutations) that confer the highest t-MN risk. Sensitive genomic assays, such as those previously described by Kirkizlar et al. 144 , should also be performed to identify low frequency clonal aneuploidy, as this may also prove predictive of t-MN. Ultimately, data addressing these questions should inform treatment decisions for at-risk patients at the time of the primary malignancy and provide a molecular test for long-term monitoring.
Based on the findings of such studies, therapies for the primary malignant disease could be tailored to decrease the risk of t-MN, for example, by avoiding the use or decreasing the dose of alkylating agents in genetically susceptible populations and/or through the continued reduction of radiation fields and dosages. Perhaps allogeneic HSCT donors should be screened for the presence of CHIP, and autologous HSCT should be avoided in patients with CHIP 122, 145 . We also expect that non-cytotoxic therapies will be less leukaemogenic. For instance, differentiation therapy can promote maturation of cancer stem cells without eliminating healthy HSCs 146 . All-trans retinoic acid is a drug that induces differentiation of acute promyelocytic leukaemia (APL) cells without negatively affecting normal HSCs 146 . Based on the emerging picture of how alterations of the bone marrow niche contribute to t-MN, future chemoprevention studies targeting changes in the niche -for example, WNT signalling, inflammatory signalling or the p53-mediated stress response -to reduce the risk in individuals with CHIP may be warranted.
Given that a proportion of t-MN cases derive from the clonal selection of mutant HSCs 6, 120 , efforts could be directed towards preserving the healthy HSCs of patients during treatment for the primary cancer. One speculative approach to accomplish a 'clonal switch' (REF. 147 ) is based upon a homeopathic approach of 'like cures like' . For example, temporarily inhibiting p53 function by knocking down p53 during radiation treatment in mice 148 has the effect of 'levelling the playing field' , such that normal HSCs are not out-competed by p53-deficient HSCs (FIG. 6) . A similar strategy could be devised for other CHIP mutations. Another therapeutic opportunity is afforded by the high prevalence of del(5q) and -7/del(7q) abnormalities, for which the cellular requirement for a normal dosage of essential genes within the CGSs may create an opportunity to target vulnerabilities due to a reduction in the level of the protein product of a haploinsufficient gene. This situation has been demonstrated in the case of lenalidomide-induced ubiquitin-mediated degradation of casein kinase Iα (CKIα), which creates a therapeutic window for targeting the affected cells in MDS with isolated del(5q) [149] [150] [151] .
Conclusions and future directions
Recent studies have provided remarkable new discoveries on the pathobiology of t-MN along the entire timeline of t-MN development. Inherited mutations in DNA repair pathways are associated with t-MN development in a small subset of patients [33] [34] [35] . Pre-existing somatic mutations acquired before treatment are selected for by chemotherapy and/or radiation 6, 120 . During one or more rounds of chemotherapy, we propose that mutant leukaemia-initiating clones are selected for increased 'fitness' in response to therapy and thus are inherently chemoresistant. Altered function of the bone marrow niche may precede cytotoxic therapy, or treatment may damage the microenvironment, providing another source selecting for the outgrowth of preleukaemic clones [12] [13] [14] [15] . Subsequent somatic mutations in t-MN are shared with other high-risk myeloid neoplasms, which is indicative of a shared aetiology [6] [7] [8] . Finally, haploinsufficiency and CGSs are now recognized as major drivers of disease [9] [10] [11] . In the future, we anticipate the discovery that other secondary cancers have comparable aetiology. Indeed, primary cancers in general likely have similar contributions from genetic predisposition, somatic clonal mosaicism (reviewed in REF. 152) and environment.
Despite these significant strides, many unanswered questions remain. It is essential to continue to classify t-MN separately from de novo AML so that these questions can be addressed. For example, what is the mechanism for clonal dominance? It should be determined if genes mutated in CHIP alter proliferation, quiescence, senescence, apoptosis or some other pathway to increase 'fitness' . Do specific genes mutated in CHIP confer increased fitness only in certain contexts? Why do some chemotherapeutic agents and not others promote clonal competition? Does this selectivity correlate with the extent to which the DNA damage responses are triggered? What is the full compendium of genes on chromosomes 5 and 7 involved in CGSs, and how do 5q-and 7q-encoded genes interact to drive haematopoietic transformation and promote clonal outgrowth? Is there a role for non-coding genes on 5q or 7q in addition to mir-145 and mir-146A 69, 72 ? Do variations in the size or span of CGS deletions cause different phenotypes? What 'M' ) at the expense of healthy HSCs during treatment of the primary cancer. One hypothetical approach towards preserving the healthy HSCs is to temporarily recapitulate the mutation in the healthy HSCs, such that no HSC clone has a 'fitness' advantage over the others. For example, in patients with a somatic TP53 mutation, a p53 inhibitor administered during chemotherapy and/or radiation treatment would prevent normal HSCs from being out-competed by TP53-mutant HSCs. A similar strategy could be devised for other clonal haematopoiesis of indeterminate potential (CHIP) mutations. 
